REGULATIONS OF ORPHAN DRUGS IN USA, EU AND INDIA-A COMPARATIVE STUDY
Journal Title: International Journal of Drug Regulatory Affairs - Year 2016, Vol 4, Issue 3
Abstract
Orphan drugs are the drugs and natural products used in treatment, diagnosis, or prevention of rare disease. The orphan drug regulation varies in different countries. Initially a guideline (Orphan Drug Act) for orphan drugs has been made in the USA. Exemption from application filing fees, tax credits for clinical research, marketing exclusivity for definite period of time and grant for phase I/II clinical trials are among the benefits given to the manufacturer of orphan drugs. As a result of these benefits number of drugs for the treatment of rare disease has been increased significantly in the last few decades. The orphan drug program can help the pharmaceutical companies in earning profit and recovering their investment even with small patient population in the developed countries. In 2001 a conference was held by the Indian Drugs Manufactures Association (IDMA) where a group of pharmacologists requested the Indian Government to establish the Orphan Drug Act in India. Indian rare disease population depends on developed countries approved orphan drugs because regulation for the orphan drugs has not been made by the Indian government. Developing countries are also feeling they should do something to promote the research and manufacturing of orphan drugs. The scarcity of regulation of orphan drugs adversely affects the economic growth of Indian medicinal industries. The present study reviews the orphan drug regulations in US, EU and India and raises some of the recent issues concerned to their regulation. .
Authors and Affiliations
Budhwar Vikaas, Singh Ajay K, Choudhary Manjusha
Keywords
Related Articles
- EP ID EP337030
- DOI 10.22270/ijdra.v4i3.187
- Views 110
- Downloads 0
DIRECTION TO REACH CLOSER TO THE EFFECTIVE LABELING OF DRUGS WITH CRITICAL PARAMETERS
Labeling of drugs is an art of expressing information, instructions, caution or warning etc. in both word and pictorial form which must be readable without magnifying glass or visualizing aids. Font size and background o...
SUPAC OF IMMEDIATE-RELEASE, MODIFIED- RELEASE AND SEMI-SOLID: A REGULATORY NOTE
In today scenario, as per market demand there is definitely carry out an increment or decrease in production, this is called SUPAC. Different guidelines are provided for those different types of SUPAC in by different reg...
INTERNATIONAL CONFERENCE ON HARMONISATION: AN OVERVIEW
The International Conference on Harmonisation (ICH) is a project that makes together the regulatory bodies of Europe, Japan and the United States and professionals from the pharmaceutical domain in the three areas to dis...
Regulatory requirements for preparation of Dossier for registration of Pharmaceutical products in ACTD & CTD format
To prepare and compile the Dossier required for Registration of Pharmaceutical Products as per the requirements of each countries which shall be acceptable internationally to develop one regulatory approach. To avoid var...
ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF DILTIAZEM HYDROCHLORIDE IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP- HPLC
A simple, specific, precise and accurate Reverse Phase High Performance Liquid Chromatography (RP-HPLC) method was developed and validated for the estimation of Diltiazem Hydrochloride in bulk and pharmaceutical dosage f...